Jax DiEugenio

Dr Qiu on the Efficacy and Safety of Eque-Cel in Relapsed/Refractory Multiple Myeloma

October 7th 2025

Luqui Qiu, MD, discusses the efficacy and safety of eque-cel in patients with relapsed or refractory multiple myeloma.

NICE Recommends First-Line Lorlatinib for Newly Diagnosed ALK+ NSCLC

October 7th 2025

Lorlatinib has received NICE’s recommendation for untreated advanced non–small cell lung cancer.

sNDA Submitted in Japan for T-DXd Plus Pertuzumab in HER2+ Advanced Breast Cancer

October 7th 2025

A new drug application was submitted to Japan’s Ministry of Health, Labour and Welfare for T-DXd plus pertuzumab for HER2-positive breast cancer.

HyBryte Has an Acceptable Safety Profile in Cutaneous T-Cell Lymphoma

October 7th 2025

A Data Monitoring Committee confirmed that the safety profile of HyBryte is acceptable and that the agent is not associated with safety concerns in CTCL.

Linvoseltamab Demonstrates Potential for Early Intervention in High-Risk Smoldering Multiple Myeloma

October 7th 2025

Paula Rodriguez-Otero, MD, discusses linvoseltamab’s potential role in the management of high-risk smoldering myeloma.

FDA Approval of Intravesical Mitomycin in NMIBC Follows ODAC Debate on Need for Randomized Data

October 7th 2025

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma

October 6th 2025

Andrew Yee, MD, discusses lenalidomide plus ixazomib,​ dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

October 6th 2025

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Dr LeVee on Limitations of the ASCENT-04 Trial of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

October 6th 2025

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC

October 6th 2025

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL

October 6th 2025

BTK inhibitor therapy improved PFS vs chemoimmunotherapy in NOTCH1-mutated CLL, highlighting the value of NOTCH1 screening to guide treatment selection.

Bevacizumab Plus Erlotinib Shows Antitumor Activity in Advanced Papillary Renal Cell Carcinoma

October 6th 2025

Phase 2 data showed bevacizumab plus erlotinib active in papillary RCC, with 72% responses in HLRCC-associated and 35% in sporadic disease.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL

October 3rd 2025

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

Dr Daver on Persisting Gaps in the Treatment of Relapsed/Refractory Higher-Risk MDS

October 3rd 2025

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Real-World Study Demonstrates Safety and Efficacy of Avelumab/Axitinib in Advanced RCC

October 3rd 2025

A real-world analysis shows avelumab plus axitinib is safe and effective in advanced RCC.

Dr LeVee on Selecting and Sequencing ADCs in Breast Cancer

October 2nd 2025

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

Experts Reflect on Ideas From MiBA 2025 That Will Propel the Future of AI-Driven Oncology

October 2nd 2025

Oncology experts and AI advocates discuss insights about how AI can help manage tasks, keep up with evolving treatment practices, and improve patient care.

Dr Rischin on the Safety of Adjuvant Cemiplimab in High-Risk CSCC

October 1st 2025

Danny Rischin, MD, discusses safety findings from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Dr Olmos on Evaluating HRR Alterations in mHSPC

October 1st 2025

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.